I-R&D ye-Sorrento igxile ekuqhubeni izinto ezintsha kwi-COVID-19, unyango lomhlaza, ulawulo olupheleleyo lweentlungu kunye nezifo ezizimelayo.

IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Iinkqubo ze-COVID-19
COVISTIX™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo 0%* Ugunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) eMexico (COFEPRIS), eBrazil (ANVISA), kunye neCE Ephawulwe eYurophu COVIMARK™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo 0%* Isicelo singeniswe e-US naseKhanada kuGunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) COVISHIELD™ (unyango) I-Antibody engathathi hlangothi (IN) kwiZigulana eziNgaphandle nakwizigulana ezilaliswayo 40%* COVISHIELD™ (unyango) I-Antibody engathathi hlangothi (IV) kwiZigulana eziNgaphandle nakwizigulana ezilaliswayo 20%* FUJOVEE™ (Abivertinib) Emandundu COVID-19 kwizigulana zase-ICU 82%* Uvavanyo olungundoqo olulindele uCwangciso lwe-FDA OQORY™ (COVI-MSC) I-ARDS ngenxa ye-COVID-19 kwizigulana zase-ICU 82%* Uvavanyo olubalulekileyo eBrazil Mpro Isithinteli (ipilisi yomlomo) Anti-intsholongwane 40%* Ugonyo lwe-Omicron mRNA Igciwane 20%*
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
immunotherapy
FUJOVEE™ (Abivertinib) I-NSCLC 82%* FUJOVEE™ (Abivertinib) B IiLymphomas zeeseli 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* FUJOVEE™ (Abivertinib) Lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) I-GvHD 20%* PD-L1 (Socazolimab)* I-SCLC 82%* *Ngentsebenziswano neLee's Pharm eTshayina I-PD-L1 (STI-3031)** Ngomhlaza wesibeleko 82%* **E-US kunye nentsebenziswano ne-ImmuneOncia eKorea CD47 Amathumba aqinileyo 40%* I-CD38 DAR-T Multiel Myeloma 40%* CD38 ADC I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal 40%* TROP2 ADC* Amathumba aqinileyo 40%* * ETshayina Intsholongwane kaSeprehvec™ oncolytic Amathumba aqinileyo; CNS Amathumba 40%* BCMA ADC Amathumba olwelo 20%* Bevacizumab-ADAB™ Umhlaza weSifo seNtsholongwane 40%* Ngentsebenziswano neMayo Clinic Bevacizumab-ADAB™ I-Ovarian Cancer 40%* Ngentsebenziswano neMayo Clinic I-Rituximab-ADAB™ I-B-cell Lymphomas 40%* Ngentsebenziswano neMayo Clinic
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Ubuhlungu
I-ZTlido™ 1.8% I-Posterpetic Neuralgia - PHN 99.8%* I-SP-102 (SEMDEXA) I-Lumbar Radicular / Sciatica Pain 82%* I-SP-103 (I-Lidocaine Topical System 5.4%) Ubuhlungu be-Acute back 20%* I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Fibromyalgia 20%* I-RTX (i-resiniferatoxin) Isitofu se-epidural Intlungu engenakunyanzeliswa kwi-Cancer Advanced 60.3%* Ukubizwa kwenkedama I-RTX (i-resiniferatoxin) Indlela ye-Intra-articular Iintlungu ze-OA zedolo eliPhakathi ukuya kutsho kweMandundu 60.2%*
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Ukuhanjiswa kweLymphatic
Sofusa® I-anti-TNF Amajoni omzimba (RA) 40%* Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL) 40%* Sofusa® anti-CTLA-4 IMelanoma 40%* Ngentsebenziswano neMayo Clinic

Iinkqubo ze-COVID-19
IiNkqubo eziPhambili (Isalathiso)	Isigaba
COVISTIX™ (uxilongo) FDA EUA COVIMARK™ (uxilongo) FDA EUA COVISHIELD™ (unyango) PH I COVISHIELD™ (unyango) Ulungelelaniso FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III I-Mpro Inhibitor (ipilisi yomlomo) (anti-viral) Ph I Ugonyo lwe-Omicron mRNA (isitofu) Ulungelelaniso

immunotherapy
IiNkqubo eziPhambili (Isalathiso)	Isigaba
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II FUJOVEE™ (Abivertinib) (Prostate) Ulungelelaniso FUJOVEE™ (Abivertinib) (Lupus) Ulungelelaniso FUJOVEE™ (Abivertinib) (NKSK) Ulungelelaniso FUJOVEE™ (Abivertinib) (GvHD) Ulungelelaniso PD-L1 (Socazolimab)*(SCLC) Ph III I-PD-L1 (STI-3031)** (Umhlaza woMlomo weSibeleko) Ph III CD47 (Iithumba eziqinileyo) Ph I I-CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal) Ph I TROP2 ADC* (Iithumba eziqinileyo) Ph I Intsholongwane kaSeprehvec™ oncolytic (Iithumba eziqinileyo; CNS Tumors) PH I BCMA ADC (Amathumba olwelo) Ulungelelaniso Bevacizumab-ADAB™ (Umhlaza we-Endometrial) Ph I Bevacizumab-ADAB™ (Umhlaza wesibeleko) Ph I I-Rituximab-ADAB™ (B-cell Lymphomas) Ph I

Ubuhlungu
IiNkqubo eziPhambili (Isalathiso)	Isigaba
I-ZTlido™ 1.8% (I-Postherpetic Neuralgia - PHN) Ukuvunyelwa kwe-FDA I-SP-102 (SEMDEXA) Ph III I-SP-103 (I-Lidocaine Topical System 5.4%) Ulungelelaniso I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Ulungelelaniso I-RTX (resiniferatoxin) inaliti ye-epidural (Iintlungu ezinganyangekiyo kuMhlaza oPhezulu) Ph II I-RTX (resiniferatoxin) Indlela ye-intra-articular (Iintlungu zedolo eliphakathi ukuya kweOA kakhulu) Ph II

Ukuhanjiswa kweLymphatic
IiNkqubo eziPhambili (Isalathiso)	Isigaba II
Sofusa® I-anti-TNF (Autoimmune RA) Ph I Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I Sofusa® anti-CTLA-4 (Imelanoma) Ph I